{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T10:05:19Z","timestamp":1794737119885,"version":"4.9.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41573-025-01225-1","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T05:04:08Z","timestamp":1751864648000},"page":"870-887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["The changing landscape of medicinal chemistry optimization"],"prefix":"10.1038","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8271-9841","authenticated-orcid":false,"given":"Anita","family":"R\u00e1cz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1022-3294","authenticated-orcid":false,"given":"Levente M.","family":"Mihalovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5988-1322","authenticated-orcid":false,"given":"Maximilian","family":"Beckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3852-3950","authenticated-orcid":false,"given":"Nikolas","family":"Fechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2562-7080","authenticated-orcid":false,"given":"Nikolaus","family":"Stiefl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finton","family":"Sirockin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2977-1744","authenticated-orcid":false,"given":"William","family":"McCoull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Evertsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8718-9421","authenticated-orcid":false,"given":"Malin","family":"Lemurell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Makara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-7809","authenticated-orcid":false,"given":"Gy\u00f6rgy M.","family":"Keser\u0171","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"1225_CR1","unstructured":"Hirschler, B. Data shows declining productivity in drug R&D. Reuters https:\/\/www.reuters.com\/article\/us-pharmaceuticals-rd-idUSTRE65Q3IM20100627 (2010)."},{"key":"1225_CR2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","volume":"11","author":"JW Scannell","year":"2012","unstructured":"Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191\u2013200 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1225_CR3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrd4320","volume":"13","author":"U Schulze","year":"2014","unstructured":"Schulze, U., Baedeker, M., Chen, Y. T. & Greber, D. R&D productivity: on the comeback trail. Nat. Rev. Drug Discov. 13, 331\u2013332 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1225_CR4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nrd3405","volume":"10","author":"F Pammolli","year":"2011","unstructured":"Pammolli, F., Magazzini, L. & Riccaboni, M. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10, 428\u2013438 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1225_CR5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","volume":"9","author":"SM Paul","year":"2010","unstructured":"Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge. Nat. Rev. Drug Discov. 9, 203\u2013214 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1225_CR6","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-016-0838-4","volume":"14","author":"A Schuhmacher","year":"2016","unstructured":"Schuhmacher, A., Gassmann, O. & Hinder, M. Changing R&D models in research-based pharmaceutical companies. J. Transl. Med. 14, 105 (2016).","journal-title":"J. Transl. Med."},{"key":"1225_CR7","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/17460441.2020.1776257","volume":"15","author":"M Patel","year":"2020","unstructured":"Patel, M. & Bueters, T. Can quantitative pharmacology improve productivity in pharmaceutical research and development? Expert Opin. Drug Discov. 15, 1111\u20131114 (2020).","journal-title":"Expert Opin. Drug Discov."},{"key":"1225_CR8","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-020-02313-z","volume":"18","author":"F Pammolli","year":"2020","unstructured":"Pammolli, F. et al. The endless frontier? The recent increase of R&D productivity in pharmaceuticals. J. Transl. Med. 18, 162 (2020).","journal-title":"J. Transl. Med."},{"key":"1225_CR9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/d41573-022-00025-1","volume":"21","author":"MKP Jayatunga","year":"2022","unstructured":"Jayatunga, M. K. P., Xie, W., Ruder, L., Schulze, U. & Meier, C. AI in small-molecule drug discovery: a coming wave? Nat. Rev. Drug Discov. 21, 175\u2013176 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1225_CR10","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.1021\/acs.jmedchem.1c00416","volume":"64","author":"PD Leeson","year":"2021","unstructured":"Leeson, P. D. et al. Target-based evaluation of \u2018drug-like\u2019 properties and ligand efficiencies. J. Med. Chem. 64, 7210\u20137230 (2021).","journal-title":"J. Med. Chem."},{"key":"1225_CR11","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103670","volume":"28","author":"A Lanne","year":"2023","unstructured":"Lanne, A. et al. A perspective on the changing landscape of HTS. Drug Discov. Today 28, 103670 (2023).","journal-title":"Drug Discov. Today"},{"key":"1225_CR12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd2796","volume":"8","author":"GM Keser\u00fc","year":"2009","unstructured":"Keser\u00fc, G. M. & Makara, G. M. The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug Discov. 8, 203\u2013212 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1225_CR13","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","volume":"6","author":"PD Leeson","year":"2007","unstructured":"Leeson, P. D. & Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6, 881\u2013890 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1225_CR14","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1021\/jm100118x","volume":"53","author":"E Perola","year":"2010","unstructured":"Perola, E. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. J. Med. Chem. 53, 2986\u20132997 (2010).","journal-title":"J. Med. Chem."},{"key":"1225_CR15","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1021\/ci000403i","volume":"41","author":"MM Hann","year":"2001","unstructured":"Hann, M. M., Leach, A. R. & Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41, 856\u2013864 (2001).","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"1225_CR16","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1021\/ci010366a","volume":"41","author":"TI Oprea","year":"2001","unstructured":"Oprea, T. I., Davis, A. M., Teague, S. J. & Leeson, P. D. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 41, 1308\u20131315 (2001).","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"1225_CR17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nrd3701","volume":"11","author":"MM Hann","year":"2012","unstructured":"Hann, M. M. & Keser\u00fc, G. M. Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Nat. Rev. Drug Discov. 11, 355\u2013365 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1225_CR18","doi-asserted-by":"crossref","first-page":"9442","DOI":"10.1021\/acs.jmedchem.8b00675","volume":"61","author":"DG Brown","year":"2018","unstructured":"Brown, D. G. & Bostr\u00f6m, J. Where do recent small molecule clinical development candidates come from? J. Med. Chem. 61, 9442\u20139468 (2018).","journal-title":"J. Med. Chem."},{"key":"1225_CR19","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1021\/acs.jmedchem.3c00521","volume":"66","author":"DG Brown","year":"2023","unstructured":"Brown, D. G. An analysis of successful hit-to-clinical candidate pairs. J. Med. Chem. 66, 7101\u20137139 (2023).","journal-title":"J. Med. Chem."},{"key":"1225_CR20","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1021\/acs.jcim.2c00785","volume":"62","author":"M Beckers","year":"2022","unstructured":"Beckers, M., Fechner, N. & Stiefl, N. 25\u2009years of small-molecule optimization at Novartis: a retrospective analysis of chemical series evolution. J. Chem. Inf. Model. 62, 6002\u20136021 (2022).","journal-title":"J. Chem. Inf. Model."},{"key":"1225_CR21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd.2017.244","volume":"17","author":"P Morgan","year":"2018","unstructured":"Morgan, P. et al. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat. Rev. Drug Discov. 17, 167\u2013181 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1225_CR22","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1021\/acs.jmedchem.1c02106","volume":"65","author":"PS Dragovich","year":"2022","unstructured":"Dragovich, P. S., Haap, W., Mulvihill, M. M., Plancher, J.-M. & Stepan, A. F. Small-molecule lead-finding trends across the Roche and Genentech research organizations. J. Med. Chem. 65, 3606\u20133615 (2022).","journal-title":"J. Med. Chem."},{"key":"1225_CR23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrd.2016.213","volume":"16","author":"RA Goodnow","year":"2017","unstructured":"Goodnow, R. A., Dumelin, C. E. & Keefe, A. D. DNA-encoded chemistry: enabling the deeper sampling of chemical space. Nat. Rev. Drug Discov. 16, 131\u2013147 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1225_CR24","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1021\/acscentsci.0c00229","volume":"6","author":"F Gentile","year":"2020","unstructured":"Gentile, F. et al. Deep docking: a deep learning platform for augmentation of structure based drug discovery. ACS Cent. Sci. 6, 939\u2013949 (2020).","journal-title":"ACS Cent. Sci."},{"key":"1225_CR25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41586-021-04220-9","volume":"601","author":"AA Sadybekov","year":"2022","unstructured":"Sadybekov, A. A. et al. Synthon-based ligand discovery in virtual libraries of over 11\u2009billion compounds. Nature 601, 452\u2013459 (2022).","journal-title":"Nature"},{"key":"1225_CR26","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101681","volume":"23","author":"OO Grygorenko","year":"2020","unstructured":"Grygorenko, O. O. et al. Generating multibillion chemical space of readily accessible screening compounds. iScience 23, 101681 (2020).","journal-title":"iScience"},{"key":"1225_CR27","doi-asserted-by":"crossref","first-page":"14261","DOI":"10.1021\/acs.jmedchem.2c01147","volume":"65","author":"PW Kenny","year":"2022","unstructured":"Kenny, P. W. Hydrogen-bond donors in drug design. J. Med. Chem. 65, 14261\u201314275 (2022).","journal-title":"J. Med. Chem."},{"key":"1225_CR28","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1002\/(SICI)1521-3773(19991216)38:24<3743::AID-ANIE3743>3.0.CO;2-U","volume":"38","author":"SJ Teague","year":"1999","unstructured":"Teague, S. J., Davis, A. M., Leeson, P. D. & Oprea, T. The design of leadlike combinatorial libraries. Angew. Chem. Int. Ed. 38, 3743\u20133748 (1999).","journal-title":"Angew. Chem. Int. Ed."},{"key":"1225_CR29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3\u201325 (1997).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1225_CR30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cbpa.2004.04.003","volume":"8","author":"MM Hann","year":"2004","unstructured":"Hann, M. M. & Oprea, T. I. Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol. 8, 255\u2013263 (2004).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"1225_CR31","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1021\/acs.jmedchem.8b00686","volume":"62","author":"MD Shultz","year":"2019","unstructured":"Shultz, M. D. Two decades under the influence of the rule of five and the changing properties of approved oral drugs. J. Med. Chem. 62, 1701\u20131714 (2019).","journal-title":"J. Med. Chem."},{"key":"1225_CR32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41570-022-00451-0","volume":"7","author":"IV Hartung","year":"2023","unstructured":"Hartung, I. V., Huck, B. R. & Crespo, A. Rules were made to be broken. Nat. Rev. Chem. 7, 3\u20134 (2023).","journal-title":"Nat. Rev. Chem."},{"key":"1225_CR33","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1021\/acs.jmedchem.5b01286","volume":"59","author":"BC Doak","year":"2016","unstructured":"Doak, B. C., Zheng, J., Dobritzsch, D. & Kihlberg, J. How beyond rule of 5 drugs and clinical candidates bind to their targets. J. Med. Chem. 59, 2312\u20132327 (2016).","journal-title":"J. Med. Chem."},{"key":"1225_CR34","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.chembiol.2014.08.013","volume":"21","author":"BC Doak","year":"2014","unstructured":"Doak, B. C., Over, B., Giordanetto, F. & Kihlberg, J. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem. Biol. 21, 1115\u20131142 (2014).","journal-title":"Chem. Biol."},{"key":"1225_CR35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/17460441.2017.1264385","volume":"12","author":"BC Doak","year":"2017","unstructured":"Doak, B. C. & Kihlberg, J. Drug discovery beyond the rule of 5\u2014opportunities and challenges. Expert Opin. Drug Discov. 12, 115\u2013119 (2017).","journal-title":"Expert Opin. Drug Discov."},{"key":"1225_CR36","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1021\/acs.jmedchem.2c01577","volume":"66","author":"DH O\u2019 Donovan","year":"2023","unstructured":"O\u2019 Donovan, D. H., De Fusco, C., Kuhnke, L. & Reichel, A. Trends in molecular properties, bioavailability, and permeability across the bayer compound collection. J. Med. Chem. 66, 2347\u20132360 (2023).","journal-title":"J. Med. Chem."},{"key":"1225_CR37","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103344","volume":"28","author":"S Stegemann","year":"2023","unstructured":"Stegemann, S. et al. Trends in oral small-molecule drug discovery and product development based on product launches before and after the rule of five. Drug Discov. Today 28, 103344 (2023).","journal-title":"Drug Discov. Today"},{"key":"1225_CR38","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.drudis.2016.06.007","volume":"21","author":"JG Kettle","year":"2016","unstructured":"Kettle, J. G. & Wilson, D. M. Standing on the shoulders of giants: a retrospective analysis of kinase drug discovery at AstraZeneca. Drug Discov. Today 21, 1596\u20131608 (2016).","journal-title":"Drug Discov. Today"},{"key":"1225_CR39","doi-asserted-by":"crossref","first-page":"103366","DOI":"10.1016\/j.drudis.2022.103366","volume":"27","author":"P Agarwal","year":"2022","unstructured":"Agarwal, P., Huckle, J., Newman, J. & Reid, D. L. Trends in small molecule drug properties: a developability molecule assessment perspective. Drug Discov. Today 27, 103366 (2022).","journal-title":"Drug Discov. Today"},{"key":"1225_CR40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41570-025-00688-5","volume":"9","author":"I Churcher","year":"2025","unstructured":"Churcher, I., Newbold, S. & Murray, C. W. Return to flatland. Nat. Rev. Chem. 9, 140\u2013141 (2025).","journal-title":"Nat. Rev. Chem."},{"key":"1225_CR41","doi-asserted-by":"crossref","first-page":"6421","DOI":"10.1021\/acs.jmedchem.8b00180","volume":"61","author":"RJ Young","year":"2018","unstructured":"Young, R. J. & Leeson, P. D. Mapping the efficiency and physicochemical trajectories of successful optimizations. J. Med. Chem. 61, 6421\u20136467 (2018).","journal-title":"J. Med. Chem."},{"key":"1225_CR42","doi-asserted-by":"crossref","first-page":"107059","DOI":"10.1016\/j.phrs.2024.107059","volume":"200","author":"R Roskoski","year":"2024","unstructured":"Roskoski, R. Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update. Pharmacol. Res. 200, 107059 (2024).","journal-title":"Pharmacol. Res."},{"key":"1225_CR43","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22132","volume":"85","author":"RS Cheke","year":"2024","unstructured":"Cheke, R. S. & Kharkar, P. S. Covalent inhibitors: an ambitious approach for the discovery of newer oncotherapeutics. Drug Dev. Res. 85, e22132 (2024).","journal-title":"Drug Dev. Res."},{"key":"1225_CR44","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1021\/acs.jmedchem.4c02661","volume":"68","author":"SE Dalton","year":"2025","unstructured":"Dalton, S. E., Di Pietro, O. & Hennessy, E. A medicinal chemistry perspective on FDA-approved small molecule drugs with a covalent mechanism of action. J. Med. Chem. 68, 2307\u20132313 (2025).","journal-title":"J. Med. Chem."},{"key":"1225_CR45","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1093\/bib\/bbz122","volume":"21","author":"J Paananen","year":"2020","unstructured":"Paananen, J. & Fortino, V. An omics perspective on drug target discovery platforms. Brief. Bioinform. 21, 1937\u20131953 (2020).","journal-title":"Brief. Bioinform."},{"key":"1225_CR46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/proteomes11040034","volume":"11","author":"T Ivanisevic","year":"2023","unstructured":"Ivanisevic, T. & Sewduth, R. N. Multi-omics integration for the design of novel therapies and the identification of novel biomarkers. Proteomes 11, 34 (2023).","journal-title":"Proteomes"},{"key":"1225_CR47","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","volume":"8","author":"X Xie","year":"2023","unstructured":"Xie, X. et al. Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials. Signal Transduct. Target. Ther. 8, 335 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1225_CR48","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.drudis.2021.08.006","volume":"26","author":"SJ Hughes","year":"2021","unstructured":"Hughes, S. J., Testa, A., Thompson, N. & Churcher, I. The rise and rise of protein degradation: opportunities and challenges ahead. Drug Discov. Today 26, 2889\u20132897 (2021).","journal-title":"Drug Discov. Today"},{"key":"1225_CR49","doi-asserted-by":"crossref","first-page":"101062","DOI":"10.1016\/j.xcrp.2022.101062","volume":"3","author":"X Han","year":"2022","unstructured":"Han, X. & Sun, Y. Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy. Cell Rep. Phys. Sci. 3, 101062 (2022).","journal-title":"Cell Rep. Phys. Sci."},{"key":"1225_CR50","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/d41573-024-00170-9","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard, A. Protein degraders push into novel target space. Nat. Rev. Drug Discov. 23, 799\u2013802 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1225_CR51","doi-asserted-by":"crossref","first-page":"13106","DOI":"10.1021\/acs.jmedchem.4c01017","volume":"67","author":"M Schade","year":"2024","unstructured":"Schade, M. et al. Structural and physicochemical features of oral PROTACs. J. Med. Chem. 67, 13106\u201313116 (2024).","journal-title":"J. Med. Chem."},{"key":"1225_CR52","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41589-020-0594-x","volume":"16","author":"C Mayor-Ruiz","year":"2020","unstructured":"Mayor-Ruiz, C. et al. Rational discovery of molecular glue degraders via scalable chemical profiling. Nat. Chem. Biol. 16, 1199\u20131207 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"1225_CR53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","volume":"184","author":"SL Schreiber","year":"2021","unstructured":"Schreiber, S. L. The rise of molecular glues. Cell 184, 3\u20139 (2021).","journal-title":"Cell"},{"key":"1225_CR54","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1021\/acs.jmedchem.3c00134","volume":"66","author":"D Garcia Jimenez","year":"2023","unstructured":"Garcia Jimenez, D., Poongavanam, V. & Kihlberg, J. Macrocycles in drug discovery\u2014learning from the past for the future. J. Med. Chem. 66, 5377\u20135396 (2023).","journal-title":"J. Med. Chem."},{"key":"1225_CR55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-020-00315-3","volume":"5","author":"H Lu","year":"2020","unstructured":"Lu, H. et al. Recent advances in the development of protein\u2013protein interactions modulators: mechanisms and clinical trials. Signal Transduct. Target. Ther. 5, 213 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1225_CR56","doi-asserted-by":"crossref","first-page":"18017","DOI":"10.1021\/acs.jmedchem.4c02264","volume":"67","author":"SD Edmondson","year":"2024","unstructured":"Edmondson, S. D. Discovery of the first clinical protein degrader for the treatment of autoimmune indications: orally bioavailable and selective IRAK4 degrader KT-474. J. Med. Chem. 67, 18017\u201318021 (2024).","journal-title":"J. Med. Chem."},{"key":"1225_CR57","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1021\/acsptsci.2c00089","volume":"5","author":"C Zhao","year":"2022","unstructured":"Zhao, C. & Dekker, F. J. Novel design strategies to enhance the efficiency of proteolysis targeting chimeras. ACS Pharmacol. Transl. Sci. 5, 710\u2013723 (2022).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"1225_CR58","doi-asserted-by":"crossref","first-page":"107984","DOI":"10.1016\/j.bioorg.2024.107984","volume":"154","author":"M Malarvannan","year":"2025","unstructured":"Malarvannan, M., Unnikrishnan, S., Monohar, S., Ravichandiran, V. & Paul, D. Design and optimization strategies of PROTACs and its application, comparisons to other targeted protein degradation for multiple oncology therapies. Bioorg. Chem. 154, 107984 (2025).","journal-title":"Bioorg. Chem."},{"key":"1225_CR59","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni, H. et al. Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J. Med. Chem. 61, 6501\u20136517 (2018).","journal-title":"J. Med. Chem."},{"key":"1225_CR60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cbpa.2020.12.006","volume":"62","author":"AR Julio","year":"2021","unstructured":"Julio, A. R. & Backus, K. M. New approaches to target RNA binding proteins. Curr. Opin. Chem. Biol. 62, 13\u201323 (2021).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"1225_CR61","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1039\/D0CS01261K","volume":"50","author":"JP Falese","year":"2021","unstructured":"Falese, J. P., Donlic, A. & Hargrove, A. E. Targeting RNA with small molecules: from fundamental principles towards the clinic. Chem. Soc. Rev. 50, 2224\u20132243 (2021).","journal-title":"Chem. Soc. Rev."},{"key":"1225_CR62","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41573-022-00521-4","volume":"21","author":"JL Childs-Disney","year":"2022","unstructured":"Childs-Disney, J. L. et al. Targeting RNA structures with small molecules. Nat. Rev. Drug Discov. 21, 736\u2013762 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1225_CR63","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","volume":"25","author":"JM Tsai","year":"2024","unstructured":"Tsai, J. M., Nowak, R. P., Ebert, B. L. & Fischer, E. S. Targeted protein degradation: from mechanisms to clinic. Nat. Rev. Mol. Cell Biol. 25, 740\u2013757 (2024).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1225_CR64","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13046-021-02225-w","volume":"41","author":"AK Kwan","year":"2022","unstructured":"Kwan, A. K., Piazza, G. A., Keeton, A. B. & Leite, C. A. The path to the clinic: a comprehensive review on direct KRASG12C inhibitors. J. Exp. Clin. Cancer Res. 41, 27 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1225_CR65","doi-asserted-by":"crossref","first-page":"14425","DOI":"10.1021\/acs.jmedchem.0c01332","volume":"63","author":"A Schuffenhauer","year":"2020","unstructured":"Schuffenhauer, A. et al. Evolution of Novartis\u2019 small molecule screening deck design. J. Med. Chem. 63, 14425\u201314447 (2020).","journal-title":"J. Med. Chem."},{"key":"1225_CR66","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.122.063372","volume":"148","author":"DG Johns","year":"2023","unstructured":"Johns, D. G. et al. Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor. Circulation 148, 144\u2013158 (2023).","journal-title":"Circulation"},{"key":"1225_CR67","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1021\/acs.jcim.3c01790","volume":"64","author":"K Klarich","year":"2024","unstructured":"Klarich, K., Goldman, B., Kramer, T., Riley, P. & Walters, W. P. Thompson sampling\u2014an efficient method for searching ultralarge synthesis on demand databases. J. Chem. Inf. Model. 64, 1158\u20131171 (2024).","journal-title":"J. Chem. Inf. Model."},{"key":"1225_CR68","doi-asserted-by":"crossref","DOI":"10.1002\/wcms.1694","volume":"14","author":"Z Zhong","year":"2024","unstructured":"Zhong, Z. et al. Recent advances in deep learning for retrosynthesis. WIREs Comput. Mol. Sci. 14, e1694 (2024).","journal-title":"WIREs Comput. Mol. Sci."},{"key":"1225_CR69","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13321-024-00860-x","volume":"16","author":"L Saigiridharan","year":"2024","unstructured":"Saigiridharan, L. et al. AiZynthFinder 4.0: developments based on learnings from 3\u2009years of industrial application. J. Cheminform. 16, 57 (2024).","journal-title":"J. Cheminform."},{"key":"1225_CR70","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1021\/acsmedchemlett.3c00041","volume":"14","author":"Y Ivanenkov","year":"2023","unstructured":"Ivanenkov, Y. et al. The hitchhiker\u2019s guide to deep learning driven generative chemistry. ACS Med. Chem. Lett. 14, 901\u2013915 (2023).","journal-title":"ACS Med. Chem. Lett."},{"key":"1225_CR71","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s42256-024-00843-5","volume":"6","author":"Y Du","year":"2024","unstructured":"Du, Y. et al. Machine learning-aided generative molecular design. Nat. Mach. Intell. 6, 589\u2013604 (2024).","journal-title":"Nat. Mach. Intell."},{"key":"1225_CR72","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1021\/acsmedchemlett.0c00540","volume":"12","author":"GM Makara","year":"2021","unstructured":"Makara, G. M., Kov\u00e1cs, L., Szab\u00f3, I. & P\u0151cze, G. Derivatization design of synthetically accessible space for optimization: in silico synthesis vs deep generative design. ACS Med. Chem. Lett. 12, 185\u2013194 (2021).","journal-title":"ACS Med. Chem. Lett."},{"key":"1225_CR73","doi-asserted-by":"crossref","first-page":"btae416","DOI":"10.1093\/bioinformatics\/btae416","volume":"40","author":"K Swanson","year":"2024","unstructured":"Swanson, K. et al. ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries. Bioinformatics 40, btae416 (2024).","journal-title":"Bioinformatics"},{"key":"1225_CR74","first-page":"100050","volume":"2","author":"J Thompson","year":"2022","unstructured":"Thompson, J. et al. Optimizing active learning for free energy calculations. Artif. Intell. Life Sci. 2, 100050 (2022).","journal-title":"Artif. Intell. Life Sci."},{"key":"1225_CR75","doi-asserted-by":"publisher","unstructured":"Ren, F. et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02143-0 (2024).","DOI":"10.1038\/s41587-024-02143-0"},{"key":"1225_CR76","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1021\/jm000942e","volume":"43","author":"P Ertl","year":"2000","unstructured":"Ertl, P., Rohde, B. & Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 43, 3714\u20133717 (2000).","journal-title":"J. Med. Chem."},{"key":"1225_CR77","unstructured":"Berthold, M. R. et al. {KNIME} The {K}onstanz {I}nformation {M}iner. In Studies in Classification, Data Analysis, and Knowledge Organization (GfKL 2007) (eds Gaul, W. et al.) 319\u2013326 (Springer, 2007)."},{"key":"1225_CR78","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1021\/ci100050t","volume":"50","author":"D Rogers","year":"2010","unstructured":"Rogers, D. & Hahn, M. Extended-connectivity fingerprints. J. Chem. Inf. Model. 50, 742\u2013754 (2010).","journal-title":"J. Chem. Inf. Model."},{"key":"1225_CR79","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13321-015-0069-3","volume":"7","author":"D Bajusz","year":"2015","unstructured":"Bajusz, D., R\u00e1cz, A. & H\u00e9berger, K. Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? J. Cheminform. 7, 20 (2015).","journal-title":"J. Cheminform."},{"key":"1225_CR80","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","volume":"13","author":"AL Hopkins","year":"2014","unstructured":"Hopkins, A. L., Keser\u00fc, G. M., Leeson, P. D., Rees, D. C. & Reynolds, C. H. The role of ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discov. 13, 105\u2013121 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1225_CR81","doi-asserted-by":"crossref","first-page":"116733","DOI":"10.1016\/j.ejmech.2024.116733","volume":"277","author":"X Jin","year":"2024","unstructured":"Jin, X., Ding, N., Guo, H.-Y. & Hu, Q. Macrocyclic-based strategy in drug design: from lab to the clinic. Eur. J. Med. Chem. 277, 116733 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"1225_CR82","doi-asserted-by":"crossref","first-page":"1098331","DOI":"10.3389\/fchem.2023.1098331","volume":"11","author":"H Jiang","year":"2023","unstructured":"Jiang, H., Xiong, H., Gu, S.-X. & Wang, M. E3 ligase ligand optimization of clinical PROTACs. Front. Chem. 11, 1098331 (2023).","journal-title":"Front. Chem."},{"key":"1225_CR83","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","volume":"20","author":"D Chirnomas","year":"2023","unstructured":"Chirnomas, D., Hornberger, K. R. & Crews, C. M. Protein degraders enter the clinic\u2014a new approach to cancer therapy. Nat. Rev. Clin. Oncol. 20, 265\u2013278 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1225_CR84","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3390\/ph17040494","volume":"17","author":"RK Rej","year":"2024","unstructured":"Rej, R. K. et al. Orally bioavailable proteolysis-targeting chimeras: an innovative approach in the golden era of discovering small-molecule cancer drugs. Pharmaceuticals 17, 494 (2024).","journal-title":"Pharmaceuticals"},{"key":"1225_CR85","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.3390\/ijms25105489","volume":"25","author":"J Li","year":"2024","unstructured":"Li, J. et al. Kinase inhibitors and kinase-targeted cancer therapies: recent advances and future perspectives. Int. J. Mol. Sci. 25, 5489 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1225_CR86","doi-asserted-by":"crossref","first-page":"107386","DOI":"10.1016\/j.bioorg.2024.107386","volume":"147","author":"Z Cai","year":"2024","unstructured":"Cai, Z., Yang, Z., Li, H. & Fang, Y. Research progress of PROTACs for neurodegenerative diseases therapy. Bioorg. Chem. 147, 107386 (2024).","journal-title":"Bioorg. Chem."},{"key":"1225_CR87","doi-asserted-by":"crossref","first-page":"116725","DOI":"10.1016\/j.ejmech.2024.116725","volume":"276","author":"S Yan","year":"2024","unstructured":"Yan, S. et al. PROTAC technology: from drug development to probe technology for target deconvolution. Eur. J. Med. Chem. 276, 116725 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"1225_CR88","volume":"12","author":"Y Feng","year":"2024","unstructured":"Feng, Y., Hu, X. & Wang, X. Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics. Biomark. Res. 12, 85 (2024).","journal-title":"Biomark. Res."},{"key":"1225_CR89","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300464","volume":"18","author":"A Ciulli","year":"2023","unstructured":"Ciulli, A. et al. The 17th EFMC short course on medicinal chemistry on small molecule protein degraders. ChemMedChem 18, e202300464 (2023).","journal-title":"ChemMedChem"},{"key":"1225_CR90","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1039\/D2MD00347C","volume":"14","author":"RP Nowak","year":"2023","unstructured":"Nowak, R. P. et al. Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives. RSC Med. Chem. 14, 501\u2013506 (2023).","journal-title":"RSC Med. Chem."},{"key":"1225_CR91","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/jb\/mvad113","volume":"175","author":"T Ito","year":"2024","unstructured":"Ito, T. Protein degraders\u2014from thalidomide to new PROTACs. J. Biochem. 175, 507\u2013519 (2024).","journal-title":"J. Biochem."},{"key":"1225_CR92","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/cells13070578","volume":"13","author":"C Bouvier","year":"2024","unstructured":"Bouvier, C. et al. Breaking bad proteins\u2014discovery approaches and the road to clinic for degraders. Cells 13, 578 (2024).","journal-title":"Cells"},{"key":"1225_CR93","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-pharmtox-022123-104147","volume":"64","author":"V Oleinikovas","year":"2024","unstructured":"Oleinikovas, V., Gainza, P., Ryckmans, T., Fasching, B. & Thom\u00e4, N. H. From thalidomide to rational molecular glue design for targeted protein degradation. Annu. Rev. Pharmacol. Toxicol. 64, 291\u2013312 (2024).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"1225_CR94","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41589-023-01458-4","volume":"20","author":"JW Mason","year":"2024","unstructured":"Mason, J. W. et al. DNA-encoded library-enabled discovery of proximity-inducing small molecules. Nat. Chem. Biol. 20, 170\u2013179 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"1225_CR95","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.chembiol.2024.04.002","volume":"31","author":"M Konstantinidou","year":"2024","unstructured":"Konstantinidou, M. & Arkin, M. R. Molecular glues for protein\u2013protein interactions: progressing toward a new dream. Cell Chem. Biol. 31, 1064\u20131088 (2024).","journal-title":"Cell Chem. Biol."},{"key":"1225_CR96","doi-asserted-by":"crossref","first-page":"107000","DOI":"10.1016\/j.bioorg.2023.107000","volume":"143","author":"D Zhang","year":"2024","unstructured":"Zhang, D., Lin, P. & Lin, J. Molecular glues targeting GSPT1 in cancers: a potent therapy. Bioorg. Chem. 143, 107000 (2024).","journal-title":"Bioorg. Chem."},{"key":"1225_CR97","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3390\/molecules23081963","volume":"23","author":"SJY Macalino","year":"2018","unstructured":"Macalino, S. J. Y. et al. Evolution of in silico strategies for protein\u2013protein interaction drug discovery. Molecules 23, 1963 (2018).","journal-title":"Molecules"},{"key":"1225_CR98","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s12551-019-00570-x","volume":"11","author":"L Mabonga","year":"2019","unstructured":"Mabonga, L. & Kappo, A. P. Protein\u2013protein interaction modulators: advances, successes and remaining challenges. Biophys. Rev. 11, 559\u2013581 (2019).","journal-title":"Biophys. Rev."},{"key":"1225_CR99","first-page":"11","volume":"13","author":"W-H Shin","year":"2020","unstructured":"Shin, W.-H., Kumazawa, K., Imai, K., Hirokawa, T. & Kihara, D. Current challenges and opportunities in designing protein\u2013protein interaction targeted drugs. Adv. Appl. Bioinforma. Chem. 13, 11\u201325 (2020).","journal-title":"Adv. Appl. Bioinforma. Chem."},{"key":"1225_CR100","doi-asserted-by":"crossref","first-page":"114334","DOI":"10.1016\/j.ejmech.2022.114334","volume":"236","author":"S Wang","year":"2022","unstructured":"Wang, S. & Chen, F.-E. Small-molecule MDM2 inhibitors in clinical trials for cancer therapy. Eur. J. Med. Chem. 236, 114334 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"1225_CR101","doi-asserted-by":"crossref","first-page":"108118","DOI":"10.1016\/j.jsb.2024.108118","volume":"216","author":"S Akbarzadeh","year":"2024","unstructured":"Akbarzadeh, S., Co\u015fkun, \u00d6. & G\u00fcn\u00e7er, B. Studying protein\u2013protein interactions: latest and most popular approaches. J. Struct. Biol. 216, 108118 (2024).","journal-title":"J. Struct. Biol."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-025-01225-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-025-01225-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-025-01225-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:07:01Z","timestamp":1761847621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-025-01225-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":101,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1225"],"URL":"https:\/\/doi.org\/10.1038\/s41573-025-01225-1","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"9 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.B., N.F., F.S. and N.S. are or were employees and shareholders of Novartis Pharma. W.M., E.E. and M.L. are employees and shareholders of AstraZeneca. G.M. is a shareholder of ChemPass. G.M.K. is a scientific advisory board member of Cytocast, ChemPass and Molecure Therapeutics and a shareholder of Gedeon Richter.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}